

Ben Sprangers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7810389/publications.pdf>

Version: 2024-02-01

159
papers

5,021
citations

101543

36
h-index

118850

62
g-index

165
all docs

165
docs citations

165
times ranked

6858
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis. <i>Cell</i> , 2018, 175, 400-415.e13.	28.9	371
2	Long-Term Results in Recipients of Combined HLA-Mismatched Kidney and Bone Marrow Transplantation Without Maintenance Immunosuppression. <i>American Journal of Transplantation</i> , 2014, 14, 1599-1611.	4.7	247
3	Î³-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer's Disease. <i>Science</i> , 2009, 324, 639-642.	12.6	233
4	Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients. <i>Science Translational Medicine</i> , 2015, 7, 272ra10.	12.4	191
5	Intrarenal Resistive Index after Renal Transplantation. <i>New England Journal of Medicine</i> , 2013, 369, 1797-1806.	27.0	185
6	The Histology of Kidney Transplant Failure. <i>Transplantation</i> , 2014, 98, 427-435.	1.0	124
7	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. <i>Kidney International</i> , 2019, 95, 188-198.	5.2	116
8	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. <i>Kidney International</i> , 2014, 85, 636-640.	5.2	106
9	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
10	Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. <i>American Journal of Transplantation</i> , 2019, 19, 763-780.	4.7	102
11	Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2193-2204.	6.1	98
12	Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 315-329.	2.9	97
13	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205.	5.2	95
14	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1508-1514.	4.5	93
15	Diagnosis and treatment of lupus nephritis flares—an update. <i>Nature Reviews Nephrology</i> , 2012, 8, 709-717.	9.6	85
16	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. <i>EBioMedicine</i> , 2019, 46, 463-472.	6.1	75
17	Beneficial Effect of Rituximab in the Treatment of Recurrent Idiopathic Membranous Nephropathy after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 790-797.	4.5	74
18	Acute Renal Endothelial Injury During Marrow Recovery in a Cohort of Combined Kidney and Bone Marrow Allografts. <i>American Journal of Transplantation</i> , 2011, 11, 1464-1477.	4.7	72

#	ARTICLE	IF	CITATIONS
19	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). <i>Annals of Oncology</i> , 2015, 26, 1677-1684.	1.2	68
20	Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3100-3113.	4.7	66
21	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 281-292.	6.1	65
22	Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. <i>Kidney International</i> , 2019, 95, 1461-1470.	5.2	61
23	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2168-2183.	6.1	60
24	Xenotransplantation: Where are we in 2008?. <i>Kidney International</i> , 2008, 74, 14-21.	5.2	54
25	Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 3367-3378.	4.7	54
26	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. <i>Kidney International</i> , 2015, 87, 210-216.	5.2	52
27	The Impact of Anastomosis Time During Kidney Transplantation on Graft Loss: A Eurotransplant Cohort Study. <i>American Journal of Transplantation</i> , 2017, 17, 726-734.	4.7	52
28	The duration of asystolic ischemia determines the risk of graft failure after circulatory-dead donor kidney transplantation: A Eurotransplant cohort study. <i>American Journal of Transplantation</i> , 2018, 18, 881-889.	4.7	51
29	Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 262-269.	2.8	51
30	Late Referral of Patients With Chronic Kidney Disease: No Time to Waste. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1487-1494.	3.0	50
31	CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. <i>Leukemia</i> , 2007, 21, 1451-1459.	7.2	50
32	Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 289-297.	4.5	50
33	Allogeneic Bone Marrow Transplantation in Models of Experimental Autoimmune Encephalomyelitis: Evidence for a Graft-versus-Autoimmunity Effect. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 627-637.	2.0	47
34	Macrochimerism in Intestinal Transplantation: Association With Lower Rejection Rates and Multivisceral Transplants, Without GVHD. <i>American Journal of Transplantation</i> , 2015, 15, 2691-2703.	4.7	47
35	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. <i>American Journal of Transplantation</i> , 2015, 15, 2900-2907.	4.7	43
36	Origin of Enriched Regulatory T Cells in Patients Receiving Combined Kidney and Bone Marrow Transplantation to Induce Transplantation Tolerance. <i>American Journal of Transplantation</i> , 2017, 17, 2020-2032.	4.7	43

#	ARTICLE	IF	CITATIONS
37	Onco-Nephrology: Core Curriculum 2015. <i>American Journal of Kidney Diseases</i> , 2015, 66, 869-883.	1.9	39
38	Recurrence of glomerulonephritis after renal transplantation. <i>Transplantation Reviews</i> , 2013, 27, 126-134.	2.9	38
39	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1505-1511.	5.8	38
40	Missing Selfâ€“Induced Microvascular Rejection of Kidney Allografts: A Population-Based Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2070-2082.	6.1	38
41	Posttransplant Epstein-Barr Virus-Associated Myogenic Tumors: Case Report and Review of the Literature. <i>American Journal of Transplantation</i> , 2008, 8, 253-258.	4.7	36
42	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. <i>Clinical Transplantation</i> , 2012, 26, 393-402.	1.6	36
43	Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 404-414.	4.3	35
44	The influence of renal transplantation on retained microbialâ€“human co-metabolites. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1721-1729.	0.7	35
45	Assessing the Complex Causes of Kidney Allograft Loss. <i>Transplantation</i> , 2020, 104, 2557-2566.	1.0	35
46	The Leuven Immunomodulatory Protocol Promotes T-Regulatory Cells and Substantially Prolongs Survival After First Intestinal Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 2973-2985.	4.7	34
47	AKI in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1077-1079.	4.5	34
48	Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2413-2423.	4.7	34
49	Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines. <i>Journal of Immunology Research</i> , 2016, 2016, 1-9.	2.2	32
50	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1508-1514.	0.7	32
51	Adult-Onset ANCA-Associated Vasculitis in SAVI: Extension of the Phenotypic Spectrum, Case Report and Review of the Literature. <i>Frontiers in Immunology</i> , 2020, 11, 575219.	4.8	32
52	Idiopathic Membranous Nephropathy: Clinical and Histologic Prognostic Features and Treatment Patterns over Time at a Tertiary Referral Center. <i>American Journal of Nephrology</i> , 2012, 36, 78-89.	3.1	31
53	Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly. <i>Blood Reviews</i> , 2018, 32, 490-498.	5.7	29
54	Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2012-2022.	2.9	29

#	ARTICLE	IF	CITATIONS
55	Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review. <i>American Journal of Kidney Diseases</i> , 2021, 78, 272-281.	1.9	29
56	The dynamics of the B follicle: understanding the normal counterpart of B-cell-derived malignancies. <i>Leukemia</i> , 2007, 21, 1378-1386.	7.2	28
57	Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney Transplant Rejection using Semi-supervised Clustering. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1084-1096.	6.1	28
58	Immunosuppression: Does One Regimen Fit All?. <i>Transplantation</i> , 2011, 92, 251-261.	1.0	27
59	Ischemia-Induced DNA Hypermethylation during Kidney Transplant Predicts Chronic Allograft Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1566-1576.	6.1	27
60	FSGS: Diagnosis and Diagnostic Work-Up. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	26
61	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	5.2	26
62	Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. <i>American Journal of Kidney Diseases</i> , 2022, 79, 667-676.e1.	1.9	25
63	The Emerging Role of DNA Methylation in Kidney Transplantation: A Perspective. <i>American Journal of Transplantation</i> , 2016, 16, 1070-1078.	4.7	22
64	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>Transplantation</i> , 2016, 100, 2188-2193.	1.0	21
65	Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 697-705.	0.7	21
66	Current Methodological Challenges of Single-Cell and Single-Nucleus RNA-Sequencing in Glomerular Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1838-1852.	6.1	21
67	How to determine kidney function in cancer patients?. <i>European Journal of Cancer</i> , 2020, 132, 141-149.	2.8	20
68	Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study. <i>Diabetes Care</i> , 2019, 42, 625-634.	8.6	19
69	Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. <i>PLoS ONE</i> , 2020, 15, e0233089.	2.5	19
70	Autologous and allogeneic hematopoietic stem cell transplantation for Multiple Sclerosis: Perspective on mechanisms of action. <i>Journal of Neuroimmunology</i> , 2008, 197, 89-98.	2.3	18
71	Microscopic nephrocalcinosis in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 843-848.	0.7	17
72	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. <i>Leukemia</i> , 2018, 32, 1815-1818.	7.2	17

#	ARTICLE	IF	CITATIONS
73	Age-related changes in DNA methylation affect renal histology and post-transplant fibrosis. <i>Kidney International</i> , 2019, 96, 1195-1204.	5.2	17
74	Circulating Donor-Specific Anti-HLA Antibodies Associate With Immune Activation Independent of Kidney Transplant Histopathological Findings. <i>Frontiers in Immunology</i> , 2022, 13, 818569.	4.8	15
75	Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells. <i>Haematologica</i> , 2011, 96, 424-431.	3.5	14
76	“Time is tissue” A minireview on the importance of donor nephrectomy, donor hepatectomy, and implantation times in kidney and liver transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2653-2661.	4.7	14
77	Otelixizumab in the treatment of Type 1 diabetes mellitus. <i>Immunotherapy</i> , 2011, 3, 1303-1316.	2.0	13
78	Subclinical GvHD in non-irradiated F1 hybrids: severe lymphoid-tissue GvHD causing prolonged immune dysfunction. <i>Bone Marrow Transplantation</i> , 2011, 46, 586-596.	2.4	13
79	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. <i>Kidney International Reports</i> , 2020, 5, 627-631.	0.8	13
80	Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. <i>Acta Clinica Belgica</i> , 2018, 73, 80-89.	1.2	12
81	Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1301-1306.	2.9	12
82	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO. <i>Kidney360</i> , 2020, 1, 158-161.	2.1	12
83	Natural History of Bone Disease following Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 638-652.	6.1	12
84	Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma. <i>Case Reports in Hematology</i> , 2016, 2016, 1-5.	0.4	11
85	Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus. <i>Acta Neurologica Belgica</i> , 2018, 118, 143-151.	1.1	11
86	Improving Cancer Care for Patients With Chronic Kidney Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 188-192.	1.6	11
87	Patterns of renal osteodystrophy 1% year after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2130-2139.	0.7	11
88	The evolution of histological changes suggestive of antibody-mediated injury, in the presence and absence of donor-specific anti-HLA antibodies. <i>Transplant International</i> , 2021, 34, 1824-1836.	1.6	11
89	Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4568.	3.0	10
90	Steroid Avoidance or Withdrawal After Kidney Transplantation: A Balancing Act. <i>Transplantation</i> , 2010, 90, 350-352.	1.0	10

#	ARTICLE	IF	CITATIONS
91	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1965-1972.	0.7	10
92	Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 589-603.	4.2	10
93	Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1733-1744.	4.2	9
94	The growing pains of ifosfamide. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 500-503.	2.9	9
95	The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003140.	8.4	9
96	Recurrence and Outcome of Anti- α -Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation. <i>Kidney International Reports</i> , 2021, 6, 1888-1894.	0.8	9
97	Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathology. <i>Kidney International</i> , 2022, 102, 183-195.	5.2	9
98	Occurrence of Autoimmunity After Xenothymus Transplantation in T-Cell-Deficient Mice Depends on the Thymus Transplant Technique. <i>Transplantation</i> , 2008, 85, 640-644.	1.0	8
99	CHRONIC WOUNDS IN A KIDNEY TRANSPLANT RECIPIENT WITH MODERATE RENAL IMPAIRMENT. <i>Acta Clinica Belgica</i> , 2013, 68, 128-131.	1.2	8
100	suPAR and FSGS. <i>Transplantation</i> , 2013, 96, 368-369.	1.0	8
101	Recipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango. <i>Blood Reviews</i> , 2018, 32, 449-456.	5.7	8
102	Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss. <i>Antiviral Research</i> , 2019, 168, 203-209.	4.1	8
103	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020, 98, 1407-1418.	5.2	8
104	Drug dosing in cancer patients with decreased kidney function: A practical approach. <i>Cancer Treatment Reviews</i> , 2021, 93, 102139.	7.7	8
105	Aetiology and management of acute kidney injury in multiple myeloma. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 722-724.	0.7	7
106	Solid Tumor-Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogeneic Bone Marrow Transplantation. <i>Cancer Research</i> , 2019, 79, 2709-2721.	0.9	7
107	Pembrolizumab-related renal toxicities: diagnosis first, treatment later. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 78-80.	2.9	7
108	The Histological Picture of Indication Biopsies in the First 2 Weeks after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1484-1493.	4.5	7

#	ARTICLE	IF	CITATIONS
109	Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?. <i>Blood Reviews</i> , 2021, 45, 100718.	5.7	7
110	Static histomorphometry allows for a diagnosis of bone turnover in renal osteodystrophy in the absence of tetracycline labels. <i>Bone</i> , 2021, 152, 116066.	2.9	7
111	The Pre-Transplant Non-HLA Antibody Burden Associates With the Development of Histology of Antibody-Mediated Rejection After Kidney Transplantation. <i>Frontiers in Immunology</i> , 2022, 13, 809059.	4.8	7
112	Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. <i>Kidney International Reports</i> , 2022, 7, 1939-1950.	0.8	7
113	Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect. <i>Leukemia</i> , 2009, 23, 340-349.	7.2	6
114	Improved Anti-Tumour Adaptive Immunity Can Overcome the Melanoma Immunosuppressive Tumour Microenvironment. <i>Cancers</i> , 2019, 11, 1694.	3.7	6
115	Multiple myeloma and kidney transplantation: the beginning of a new era. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 213-215.	2.9	6
116	Haematological disorders following kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 409-420.	0.7	6
117	Small Molecule Cyclotriazadisulfonamide Abrogates the Upregulation of the Human Receptors CD4 and 4-1BB and Suppresses In Vitro Activation and Proliferation of T Lymphocytes. <i>Frontiers in Immunology</i> , 2021, 12, 650731.	4.8	6
118	Management of checkpoint inhibitor-associated renal toxicities. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 215-223.	0.6	6
119	Treatment of acute kidney injury in cancer patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 873-884.	2.9	6
120	Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2022, 80, 718-729.e1.	1.9	6
121	The Many Faces of Merlin. <i>Chest</i> , 2011, 140, 791-794.	0.8	5
122	The Hype Cycle for Soluble Urokinase Receptor in FSGS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1835-1836.	4.5	5
123	Reversal of Dialysis-Dependent Anti-Glomerular Basement Membrane Disease Using Plasma Exchange, Glucocorticosteroids, and Rituximab. <i>Kidney International Reports</i> , 2018, 3, 1229-1232.	0.8	5
124	Tyrosine kinase inhibitor-induced hypertension—marker of anti-tumour treatment efficacy or cardiovascular risk factor?. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 14-17.	2.9	5
125	Epidemiology of native kidney disease in Flanders: results from the FCGG kidney biopsy registry. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1361-1372.	2.9	5
126	Artemisinin attenuates IgM xenoantibody production via inhibition of T cell-independent marginal zone B cell proliferation. <i>Journal of Leukocyte Biology</i> , 2021, 109, 583-591.	3.3	4

#	ARTICLE	IF	CITATIONS
127	Intratumoral immunotherapy with anti- $\text{PD}^{\text{L}}1$ and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts. <i>American Journal of Transplantation</i> , 2021, 21, 60-72.	4.7	4
128	The effect of IGL-1 preservation solution on outcome after kidney transplantation: A retrospective single-center analysis. <i>American Journal of Transplantation</i> , 2021, 21, 830-837.	4.7	4
129	IgG4-related disease should be considered in cases of hypocomplementemic immune-complex tubulointerstitial nephritis. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 326-326.	2.9	3
130	Clinical case report: a rare cause of acute kidney failure – tissue is the issue. <i>Acta Clinica Belgica</i> , 2017, 72, 201-204.	1.2	3
131	Delayed Bleeding of the Transplant Duodenum After Simultaneous Kidney-pancreas Transplantation: Case Series. <i>Transplantation</i> , 2020, 104, 184-189.	1.0	3
132	Donor Lymphocyte-Derived Natural Killer Cells Control MHC Class II-Negative Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 756-768.	3.4	3
133	Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.7	3
134	Xenograft rejection – all that glitters is not Gal. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1486-1488.	0.7	2
135	Anastomosis time as risk factor for kidney transplant outcome: more pieces to the puzzle. <i>Transplant International</i> , 2015, 28, 1336-1337.	1.6	2
136	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. <i>Leukemia</i> , 2017, , .	7.2	2
137	OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics. <i>Journal of Immunology Research</i> , 2018, 2018, 1-14.	2.2	2
138	Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. <i>Advances in Chronic Kidney Disease</i> , 2022, 29, 208-216.e1.	1.4	2
139	Xenograft rejection and the innate immune system. <i>Current Opinion in Organ Transplantation</i> , 2007, 12, 142-147.	1.6	1
140	Beneficial Effect of Rituximab in the Treatment of Esophageal Cancer – Associated Pauci-Immune Glomerulonephritis. <i>Kidney International Reports</i> , 2016, 1, 131-134.	0.8	1
141	How to use dialysis wisely in cancer patients?. <i>Journal of Onco-Nephrology</i> , 2021, 5, 79-86.	0.6	1
142	Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment. <i>Cancer Letters</i> , 2021, 503, 151-162.	7.2	1
143	Determination of free light chains: assay-dependent differences in interpretation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e69-e71.	2.3	1
144	Establishment of operational tolerance to sustain antitumor immunotherapy. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 568-577.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Pediatric Organ Allocation: Matching Tissue and Needs. Transplantation, 2010, 90, 244-245.	1.0	0
146	The Case of A blistering complication of peritoneal dialysis. Kidney International, 2010, 78, 625-626.	5.2	0
147	Authors' Reply to Knight and Morris. Transplantation, 2011, 91, e26-e27.	1.0	0
148	HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. Leukemia and Lymphoma, 2016, 57, 2241-2242.	1.3	0
149	P0114BENEFITS AND CHALLENGES OF A RENAL BIOPSY REGISTRY AND NETWORK - FCGG EXPERIENCE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
150	Deconvolution of Focal Segmental Glomerulosclerosis Pathophysiology Using Transcriptomics Techniques. Glomerular Diseases, 2021, 1, 265-276.	1.0	0
151	Optimal use of corticosteroids in nephrology. Journal of Translational Internal Medicine, 2014, 2, 59-69.	2.5	0
152	Kinetics of Myeloid-Derived Suppressor Cells during Stem Cell Mobilization and Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients. Blood, 2018, 132, 2065-2065.	1.4	0
153	Title is missing!. , 2020, 17, e1003140.		0
154	Title is missing!. , 2020, 17, e1003140.		0
155	Title is missing!. , 2020, 17, e1003140.		0
156	Title is missing!. , 2020, 17, e1003140.		0
157	Title is missing!. , 2020, 17, e1003140.		0
158	Title is missing!. , 2020, 17, e1003140.		0
159	“Prevention is better than cure” warning for comedications in patients receiving immune check-point inhibitors to avoid acute kidney injury. CKJ: Clinical Kidney Journal, 0, , .	2.9	0